HC Wainwright Cuts Actuate Therapeutics (NASDAQ:ACTU) Price Target to $15.00

Actuate Therapeutics (NASDAQ:ACTU) had its price objective reduced by analysts at HC Wainwright from $20.00 to $15.00 in a research report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock.

A number of other equities analysts have also recently commented on the stock. Wall Street Zen raised shares of Actuate Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of Actuate Therapeutics in a research note on Friday, March 27th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.67.

Actuate Therapeutics Stock Performance

NASDAQ:ACTU opened at $1.72 on Monday. The firm has a market capitalization of $40.78 million, a price-to-earnings ratio of -1.64 and a beta of 0.85. Actuate Therapeutics has a 52-week low of $1.69 and a 52-week high of $11.99. The stock has a fifty day moving average of $3.23 and a 200 day moving average of $5.39.

Actuate Therapeutics (NASDAQ:ACTU) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.06.

Hedge Funds Weigh In On Actuate Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ACTU. Goldman Sachs Group Inc. grew its holdings in shares of Actuate Therapeutics by 98.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 22,358 shares of the company’s stock valued at $151,000 after purchasing an additional 11,105 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Actuate Therapeutics by 252.5% during the 2nd quarter. Geode Capital Management LLC now owns 118,050 shares of the company’s stock valued at $721,000 after purchasing an additional 84,561 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Actuate Therapeutics by 492.6% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 18,518 shares of the company’s stock valued at $113,000 after purchasing an additional 15,393 shares during the last quarter. New York State Common Retirement Fund bought a new position in shares of Actuate Therapeutics during the 2nd quarter valued at $105,000. Finally, Bank of America Corp DE grew its holdings in shares of Actuate Therapeutics by 61,068.0% during the 2nd quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock valued at $93,000 after purchasing an additional 15,267 shares during the last quarter.

Actuate Therapeutics Company Profile

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.